AAAAAA
Results: 1-25/56
Authors:
PATER J
OSOBA D
ZEE B
LOFTERS W
GORE M
DEMPSEY E
PALMER M
CHIN C
Citation: J. Pater et al., EFFECTS OF ALTERING THE TIME OF ADMINISTRATION AND THE TIME FRAME OF QUALITY-OF-LIFE ASSESSMENTS IN CLINICAL-TRIALS - AN EXAMPLE USING THE EORTC QLQ-C30 IN A LARGE ANTIEMETIC TRIAL, Quality of life research, 7(3), 1998, pp. 273-278
Authors:
HOLLANDER J
GORE M
FIEBIG R
MAZZEO R
OHISHI S
OHNO H
JI LL
Citation: J. Hollander et al., SPACEFLIGHT DOWN-REGULATES ANTIOXIDANT DEFENSE SYSTEMS IN RAT-LIVER, Free radical biology & medicine, 24(2), 1998, pp. 385-390
Authors:
KEILHOLZ U
CONRADT C
LEGHA SS
KHAYAT D
SCHEIBENBOGEN C
THATCHER N
GOEY SH
GORE M
DORVAL T
HANCOCK B
PUNT CJA
DUMMER R
AVRIL MF
BROCKER EB
BENHAMMOUDA A
EGGERMONT AMM
PRITSCH M
Citation: U. Keilholz et al., RESULTS OF INTERLEUKIN-2-BASED TREATMENT IN ADVANCED MELANOMA - A CASE RECORD-BASED ANALYSIS OF 631 PATIENTS, Journal of clinical oncology, 16(9), 1998, pp. 2921-2929
Authors:
GORE M
MAINWARING P
AHERN R
MACFARLANE V
SLEVIN M
HARPER P
OSBORNE R
MANSI J
BLAKE P
WILTSHAW E
SHEPHERD J
Citation: M. Gore et al., RANDOMIZED TRIAL OF DOSE-INTENSITY WITH SINGLE-AGENT CARBOPLATIN IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER, Journal of clinical oncology, 16(7), 1998, pp. 2426-2434
Authors:
SCHRIJVERS D
JOHNSON J
JIMINEZ U
GORE M
KOSMIDIS P
SZPIRGLAS H
ROBBINS K
OLIVEIRA J
LEWENSOHN R
SCHULLER J
RIVIERE A
ARVAY C
LANGECKER P
JACOB H
CVITKOVIC E
VOKES E
Citation: D. Schrijvers et al., PHASE-III TRIAL OF MODULATION OF CISPLATIN FLUOROURACIL CHEMOTHERAPY BY INTERFERON-ALPHA-2B IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK-CANCER/, Journal of clinical oncology, 16(3), 1998, pp. 1054-1059
Authors:
POWLES R
CUNNIGHAM D
MALPAS J
RAJE N
MILAN S
VINER C
MONTES A
HICKISH T
NICOLSON M
JOHNSON P
TRELEAVEN J
RAYMOND J
GORE M
Citation: R. Powles et al., A RANDOMIZED TRIAL OF MAINTENANCE INTERFERON FOLLOWING HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA - RESULTS 51 2 YEARS AFTER THE ACCRUAL OFTHE LAST PATIENT/, Bone marrow transplantation, 21, 1998, pp. 733-733
Authors:
POWLES R
CUNNINGHAM D
GORE M
KULKARNI S
RAMIAH V
MEHTA J
Citation: R. Powles et al., LONG-TERM FOLLOW-UP OF MYELOMA PATIENTS TREATED WITH 140 MG M-2 MELPHALAN WITHOUT AUTOLOGOUS TRANSPLANTATION/, Bone marrow transplantation, 21, 1998, pp. 735-735
Authors:
CUNNINGHAM D
POWLES R
MALPAS J
RAJE N
MILAN S
VINER C
MONTES A
HICKISH T
NICOLSON M
JOHNSON P
TRELEAVEN J
RAYMOND J
GORE M
Citation: D. Cunningham et al., A RANDOMIZED TRIAL OF MAINTENANCE INTERFERON FOLLOWING A HIGH-DOSE CHEMOTHERAPY IN MULTIPLE-MYELOMA - LONG-TERM FOLLOW-UP RESULTS, British Journal of Haematology, 102(2), 1998, pp. 495-502
Authors:
AABO K
ADAMS M
ADNITT P
ALBERTS DS
ATHANAZZIOU A
BARLEY V
BELL DR
BIANCHI U
BOLIS G
BRADY MF
BRODOVSKY HS
BRUCKNER H
BUYSE M
CANETTA R
CHYLAK V
COHEN CJ
COLOMBO N
CONTE PF
CROWTHER D
EDMONSON JH
GENNATAS C
GILBEY E
GORE M
GUTHRIE D
KAYE SB
LAING AH
LANDONI F
LEONARD RC
LEWIS C
LIU PY
MANGIONI C
MARSONI S
MEERPOHL H
OMURA GA
PARMAR MKB
PATER J
PECORELLI S
PRESTI M
SAUERBREI W
SKARLOS DV
SMALLEY RV
SOLOMON HJ
STEWART LA
STURGEON JFG
TATTERSALL MHN
WHARTON JT
HUININK WWT
TOMIROTTI M
TORRI W
TROPE C
TURBOW MM
VERMORKEN JB
WEBB MJ
WILBUR DW
WILLIAMS CJ
WILTSHAW E
YEAP BY
Citation: K. Aabo et al., CHEMOTHERAPY IN ADVANCED OVARIAN-CANCER - 4 SYSTEMATIC METAANALYSES OF INDIVIDUAL PATIENT DATA FROM 39 RANDOMIZED TRIALS, British Journal of Cancer, 78(11), 1998, pp. 1479-1487
Authors:
DUNNING AM
CHIANO M
SMITH NR
DEARDEN J
GORE M
OAKES S
WILSON C
STRATTON M
PETO J
EASTON D
CLAYTON D
PONDER BAJ
Citation: Am. Dunning et al., COMMON BRCA1 VARIANTS AND SUSCEPTIBILITY TO BREAST AND OVARIAN-CANCERIN THE GENERAL-POPULATION, Human molecular genetics, 6(2), 1997, pp. 285-289
Authors:
RUSTIN GJS
NELSTROP AE
BOLIS G
GORE M
TENBOKKELHUININK W
SPACZYNSKI M
Citation: Gjs. Rustin et al., RESPONSE AND EARLY PROGRESSION ACCORDING TO CA-125 TO ASSESS ACTIVITYOF TOPOTECAN VS PACLITAXEL IN RELAPSED OVARIAN-CARCINOMA, European journal of cancer, 33, 1997, pp. 525-525
Authors:
WANDERS J
VANOOSTEROM AT
GORE M
CALVERT AH
HUININK WWT
HANSEN HH
WISSEL P
HANAUSKE AR
Citation: J. Wanders et al., A PHASE-II STUDY WITH GI147211 IN OVARIAN-CANCER, European journal of cancer, 33, 1997, pp. 528-528
Authors:
GWYTHER SJ
GORE M
HUININK WT
FIELDS SZ
HUDSON I
Citation: Sj. Gwyther et al., INDEPENDENT RADIOLOGICAL REVIEW OF A PHASE-III STUDY OF TOPOTECAN VERSUS PACLITAXEL AS 2ND-LINE THERAPY IN ADVANCED EPITHELIAL OVARIAN-CANCER, European journal of cancer, 33, 1997, pp. 533-533
Authors:
GORDON A
BOOKMAN M
HUININK WT
GORE M
MALMSTROM H
KREBS JB
FIELDS SZ
Citation: A. Gordon et al., POOLED ANALYSIS OF PATIENTS (PTS) TREATED WITH TOPOTECAN (T) AFTER PROGRESSION OR FAILURE ON PLATINUM (FLAT) AND PACLITAXEL (P), European journal of cancer, 33, 1997, pp. 536-536
Authors:
JOHNSON S
PYLE L
KING K
GORE M
Citation: S. Johnson et al., A PHASE-II STUDY OF TOPOTECAN GIVEN AS A CONTINUOUS 21-DAY INFUSION EVERY 28 DAYS IN PLATINUM PRETREATED OVARIAN-CARCINOMA, European journal of cancer, 33, 1997, pp. 537-537
Authors:
PALMER K
EVERARD M
HARRIS J
MOORE J
GORE M
COLLINS M
Citation: K. Palmer et al., A PHASE-I CLINICAL-TRIAL FOR PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS IL2 SECRETING MELANOMA AS A VACCINE, Cancer gene therapy, 4(6), 1997, pp. 121-121
Authors:
PALMER K
EVERARD M
HARRIS J
MOORE J
GORE M
COLLINS M
Citation: K. Palmer et al., A PHASE-I CLINICAL-TRIAL FOR PATIENTS WITH METASTATIC MELANOMA USING AUTOLOGOUS IL2 SECRETING MELANOMA AS A VACCINE, Cancer gene therapy, 4(5), 1997, pp. 336-336
Authors:
GWYTHER S
BOLIS G
GORE M
HUININK WT
VERWEIJ J
HUDSON IR
DESPAX R
JIMENEZLACAVE A
Citation: S. Gwyther et al., EXPERIENCE WITH INDEPENDENT RADIOLOGICAL REVIEW DURING A TOPOTECAN TRIAL IN OVARIAN-CANCER, Annals of oncology, 8(5), 1997, pp. 463-468
Authors:
HOLLANDER J
GORE M
FIEBIG R
BEJMA J
JI LL
Citation: J. Hollander et al., EXERCISE TRAINING ALTERS SUPEROXIDE-DISMUTASE GENE-EXPRESSION IN RATS, The FASEB journal, 11(3), 1997, pp. 3379-3379
Authors:
HUININK WTB
GORE M
CARMICHAEL J
GORDON A
MALFETANO J
HUDSON I
BROOM C
SCARABELLI C
DAVIDSON N
SPANCZYNSKI M
BOLIS G
MALMSTROM H
COLEMAN R
FIELDS SC
HERON JF
Citation: Wtb. Huinink et al., TOPOTECAN VERSUS PACLITAXEL FOR THE TREATMENT OF RECURRENT EPITHELIALOVARIAN-CANCER, Journal of clinical oncology, 15(6), 1997, pp. 2183-2193
Authors:
GORE M
SHEPARD J
BLAKE P
WILTSHAW E
Citation: M. Gore et al., SYSTEMATIC SURGICAL STAGING - STAGE-I OVARIAN-CANCER - REPLY, Journal of clinical oncology, 15(2), 1997, pp. 864-865
Authors:
LEEUWENBURGH C
HOLLANDER J
LEICHTWEIS S
GRIFFITHS N
GORE M
JI LL
Citation: C. Leeuwenburgh et al., ADAPTATIONS OF GLUTATHIONE ANTIOXIDANT SYSTEM TO ENDURANCE TRAINING ARE TISSUE AND MUSCLE-FIBER SPECIFIC, American journal of physiology. Regulatory, integrative and comparative physiology, 41(1), 1997, pp. 363-369
Authors:
POWLES R
RAJE N
MILAN S
MILLAR B
SHEPHERD V
MEHTA J
SINGHAL S
KULKARNI S
VINER C
GORE M
CUNNINGHAM D
TRELEAVEN J
Citation: R. Powles et al., OUTCOME ASSESSMENT OF A POPULATION-BASED GROUP OF 195 UNSELECTED MYELOMA PATIENTS UNDER 70 YEARS OF AGE OFFERED INTENSIVE TREATMENT, Bone marrow transplantation, 20(6), 1997, pp. 435-443
Authors:
GORE M
AHERN R
SWENERTON K
Citation: M. Gore et al., GOOD MANNERS FOR THE PHARMACEUTICAL-INDUSTRY, Lancet, 350(9074), 1997, pp. 370-370
Authors:
ADAMS SL
GORE M
Citation: Sl. Adams et M. Gore, DIAGNOSTICIANS DIGIT - A REPERCUSSION OF PERCUSSION, JAMA, the journal of the American Medical Association, 277(14), 1997, pp. 1168-1168